1. Home
  2. MBIO vs QUCY Comparison

MBIO vs QUCY Comparison

Compare MBIO & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.60

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Logo Mainz Biomed N.V. Ordinary Shares

QUCY

Mainz Biomed N.V. Ordinary Shares

N/A

Current Price

$3.59

Market Cap

5.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MBIO
QUCY
Founded
2015
2008
Country
United States
Germany
Employees
N/A
13
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
5.9M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
MBIO
QUCY
Price
$0.60
$3.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
34.2K
30.0M
Earning Date
05-13-2026
06-26-2026
Dividend Yield
N/A
N/A
EPS Growth
98.99
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$74.34
Revenue Next Year
N/A
$171.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.30
52 Week High
$7.00
$3.97

Technical Indicators

Market Signals
Indicator
MBIO
QUCY
Relative Strength Index (RSI) 25.57 93.25
Support Level $0.53 $0.39
Resistance Level $0.80 N/A
Average True Range (ATR) 0.03 0.46
MACD -0.01 0.30
Stochastic Oscillator 2.74 67.06

Price Performance

Historical Comparison
MBIO
QUCY

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About QUCY Mainz Biomed N.V. Ordinary Shares

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: